Literature DB >> 15469820

GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity.

Patrick Viatour1, Emmanuel Dejardin, Michael Warnier, Florence Lair, Estefania Claudio, Fabrice Bureau, Jean-Christophe Marine, Marie-Paule Merville, Ulrich Maurer, Douglas Green, Jacques Piette, Ulrich Siebenlist, Vincent Bours, Alain Chariot.   

Abstract

The oncoprotein BCL-3 is a nuclear transcription factor that activates NF-kappaB target genes through formation of heterocomplexes with p50 or p52. BCL-3 is phosphorylated in vivo, but specific BCL-3 kinases have not been identified so far. In this report, we show that BCL-3 is a substrate for the protein kinase GSK3 and that GSK3-mediated BCL-3 phosphorylation, which is inhibited by Akt activation, targets its degradation through the proteasome pathway. This phosphorylation modulates its association with HDAC1, -3, and -6 and attenuates its oncogenicity by selectively controlling the expression of a subset of newly identified target genes such as SLPI and Cxcl1. Our results therefore suggest that constitutive BCL-3 phosphorylation by GSK3 regulates BCL-3 turnover and transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469820     DOI: 10.1016/j.molcel.2004.09.004

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  62 in total

1.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

2.  The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.

Authors:  Aurore Keutgens; Kateryna Shostak; Pierre Close; Xin Zhang; Benoît Hennuy; Marie Aussems; Jean-Paul Chapelle; Patrick Viatour; André Gothot; Marianne Fillet; Alain Chariot
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

Review 3.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

4.  Expression of the Bcl-3 proto-oncogene suppresses p53 activation.

Authors:  David Kashatus; Patricia Cogswell; Albert S Baldwin
Journal:  Genes Dev       Date:  2005-12-29       Impact factor: 11.361

Review 5.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

Authors:  Eléonore Beurel; Richard S Jope
Journal:  Prog Neurobiol       Date:  2006-08-28       Impact factor: 11.685

Review 6.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

7.  Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.

Authors:  Katie Schumm; Sonia Rocha; Jorge Caamano; Neil D Perkins
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

Review 8.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

Review 9.  Specification of DNA binding activity of NF-kappaB proteins.

Authors:  Fengyi Wan; Michael J Lenardo
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10       Impact factor: 10.005

10.  The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter.

Authors:  Young-Mi Kim; Neelam Sharma; Jennifer K Nyborg
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.